Patent and Regulatory Exclusivity Periods for GLP-1 Drugs, Explained
Patents and FDA regulatory exclusivity are two separate legal protections that both affect when competition can enter the GLP-1 market.
By the GLP Semaglutide editorial team · Last updated August 25, 2025
Patents are granted by national patent offices and protect specific inventions (like a molecule or formulation) for a set term. FDA regulatory exclusivity is a separate protection granted at approval that can block competitor approvals for a period, independent of patent status.
Why both matter for competition timing
A company can hold both patent protection and regulatory exclusivity on the same product, and competitors generally need both to have lapsed (or to successfully challenge the patent) before bringing a biosimilar or generic to market — which is why 'patent cliff' timelines are often more complex than a single expiration date suggests.
This varies by country
Both patent term and regulatory exclusivity periods are set independently by each country's law, which is a core reason biosimilar competition for the same molecule arrives at different times in different markets.
Primary sources